1. Home /
    2. Altai Protocol Library /
  2. New Indication: Cemiplimab in Recurrent Cervical Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Cemiplimab in Recurrent Cervical Cancer

New Indication: Cemiplimab in Recurrent Cervical Cancer
Study:
  • Open-label, multicenter, phase 3 trial (EMPOWER-Cervical 1)
  • Recurrent or metastatic cervical carcinoma, progressed after prior platinum-containing therapy
  • Cemiplimab (n=304) or single-agent chemotherapy (n=304)
Efficacy:
  • mOS: 12.0 mos vs. 8.5 mos; (HR: 0.69; P<0.001)
  • ORR: 16.4% vs 6.3%
Safety:
  • Grade 3 AE >= 45% vs 53.4
  • Anemia:12% vs 26.9%. Urinary tract infection 5.0% vs 2.8%

N Engl J Med. 2022 Feb 10;386(6):544-555.

Survival with Cemiplimab in Recurrent Cervical Cancer

https://doi.org/10.1056/nejmoa2112187

Reviewed by Hasan Cagri Yildirim

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More